Holen Sie sich die Stockscreener-App
11.54
1.86%
0.22
Handel nachbörslich:
11.54
Schlusskurs vom Vortag:
$11.32
Offen:
$11.28
24-Stunden-Volumen:
716.13K
Relative Volume:
0.66
Marktkapitalisierung:
$583.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-3.1274
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
+5.59%
1M Leistung:
-17.70%
6M Leistung:
-3.51%
1J Leistung:
-1.62%
1-Tages-Spanne:
$11.21
$11.78
1-Wochen-Bereich:
$10.82
$11.99
52-Wochen-Spanne:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
11.54 | 571.92M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
Will a bounce in KalVista Pharmaceuticals Inc. offer an exitTrade Analysis Summary & Weekly Stock Breakout Alerts - newser.com
What drives KalVista Pharmaceuticals Inc 4XC1 stock priceMACD Histogram Signals & Rapid Portfolio Expansion - earlytimes.in
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsTrade Volume Report & Fast Momentum Stock Entry Tips - newser.com
Ekterly eases most HAE attacks within 20 minutes, trial data show - Angioedema News
How sentiment analysis helps forecast KalVista Pharmaceuticals Inc.Gap Up & Low Risk Entry Point Guides - newser.com
Heatmap analysis for KalVista Pharmaceuticals Inc. and competitorsWeekly Profit Report & Consistent Return Strategy Ideas - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth fundsQuarterly Market Review & Fast Gain Swing Alerts - newser.com
How to track smart money flows in KalVista Pharmaceuticals Inc.July 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
Key resistance and support levels for KalVista Pharmaceuticals Inc.Weekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
What Fibonacci levels say about KalVista Pharmaceuticals Inc. reboundDay Trade & AI Enhanced Execution Alerts - newser.com
KalVista Pharmaceuticals (NASDAQ:KALV) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Can KalVista Pharmaceuticals Inc. stock sustain free cash flow growthGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
KalVista: Prophylaxis Is Shrinking The Acute HAE TAM (NASDAQ:KALV) - Seeking Alpha
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 4%Should You Sell? - MarketBeat
KalVista’s oral HAE treatment shows rapid attack control in European trials - Investing.com
KalVista (KALV) Highlights Game-Changing Oral Treatment for HAE in German Study - GuruFocus
About Us - FinancialContent
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe - The Joplin Globe
KalVista Pharmaceuticals Appoints Bilal Arif as COO and Linea Aspesi as CPO - citybiz
Kalvista Pharmaceuticals, Inc. Appoints Bilal Arif as Chief Operating Officer, Effective October 6, 2025 - MarketScreener
KalVista Pharmaceuticals Names Bilal Arif as COO, Linea Aspesi as Chief People Officer - MarketScreener
KalVista Pharmaceuticals appoints new COO and CPO - Investing.com
KalVista Pharmaceuticals appoints new COO and CPO By Investing.com - Investing.com Australia
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer - The Globe and Mail
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener
Can momentum traders help lift KalVista Pharmaceuticals Inc.Market Risk Report & Fast Moving Stock Watchlists - newser.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Tools to assess KalVista Pharmaceuticals Inc.’s risk profileWatch List & Consistent Growth Equity Picks - newser.com
Custom strategy builders for tracking KalVista Pharmaceuticals Inc.Oil Prices & Verified Technical Signals - newser.com
KalVista Pharmaceuticals Appoints Bethany Sensenig to Board - The Globe and Mail
Is KalVista Pharmaceuticals Inc. forming a bottoming base2025 Fundamental Recap & Daily Stock Momentum Reports - newser.com
Is KalVista Pharmaceuticals Inc. (4XC1) stock included in top ETFsWeekly Investment Report & Fast Moving Trade Plans - newser.com
KalVista Pharmaceuticals Appoints Bethany L. Sensenig to Board of Directors - citybiz
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors - BioSpace
KalVista Pharmaceuticals appoints Bethany Sensenig to board of directors By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals appoints Bethany Sensenig to board of directors - Investing.com India
Voya Investment Management LLC Sells 2,151 Shares of KalVista Pharmaceuticals, Inc. $KALV - Defense World
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below 50-Day Moving AverageTime to Sell? - MarketBeat
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):